Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 21, 2007, Pages 6003-6008

  Dominguez, Celia ^a   Smith, Leon ^f   Huang, Qi ^a   Yuan, Chester ^a   Ouyang, Xiaohu ^g   Cai, Lynn ^a   Chen, Paul ^g   Kim, Joseph ^a   Harvey, Timothy ^a   Syed, Rashid ^a   Kim, Tae Seong ^a   Tasker, Andrew ^a   Wang, Ling ^b   Zhang, Michael ^b   Coxon, Angela ^c   Bready, James ^c   Starnes, Charles ^c   Chen, Danlin ^c   Gan, Yongmei ^c   Neervannan, Sesha ^e   Kumar, Gondi ^d   Polverino, Anthony ^b   Kendall, Richard ^b   more..

^a Chemistry Research and Discovery   (United States)

^b Cancer Biology   (United States)

^c Cancer Pharmacology   (United States)

^d Pharmacokinetics and Drug Metabolism   (United States)

^e AMGEN INC   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g NONE   (United States)

Author keywords

Angiogenesis inhibitor; Kdr inhibitor; Kinase inhibitor; VEGF; VEGFR 2 inhibitor

Indexed keywords

N PHENYLNICOTINAMIDE DERIVATIVE; NICOTINAMIDE; SORAFENIB; SUNITINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 INHIBITOR; VASCULOTROPIN RECEPTOR 2 KINASE; VATALANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; METASTASIS; MOLECULAR MECHANICS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; STRUCTURE ACTIVITY RELATION;

CELL LINE, TUMOR; HUMANS; NIACINAMIDE; PROTEIN KINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34548818780     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.07.077     Document Type: Article

References (11)

1. Keren P., and Zhu Z. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2: current status and future perspective. Frontiers in Bioscience 10 (2005) 1415-1439
2. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21 (2000) 505-515
3. Makinen T., Jussila L., Karpanen T., Keitunen M.I., Pulkkanen K.J., Kauppinen R., Jackson D.G., Kubo H., Nishikawa S.I., Yla-Herttuala S., and Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7 (2001) 199-205
4. Veikkola T., Karkkaninen M., Claesson-Welsh L., and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60 (2000) 203-212
5. Neufeld G., Cohen T., Gengrinovich S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1999) 9-22
6. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 23 (2004) 2335-2342
7. McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.-C., Villafranca J.E., and Appelt K. Crystal structure of the kinase domain of vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7 (1999) 319-3308
8. Hennequin L.F., Thomas A.P., Johnstone C., Stokes E.S.E., Ple P.A., Lohmann J.-J.M., Ogilvie D.J., Dukes M., Wedge S.R., Curwen J.O., Kendrew J., and Lambert-van der Brempt C. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 42 26 (1999) 5369-5389
9. Chen, G., Booker, S., Cai, G. Croghan, M., Dipeitro, L., Dominguez, C., Elbaum, D., Germain, J., Huang, Q., Kim, J., Kim, T-S., Patel, V., Smith, L., Tasker, A., Xi, N., Xu, S., Yuan, C. Preparation of Substituted Arylamines and Methods of Use as Anti-tumor Agents. WO 02/055501.
10. Manley, P.W., Bold, G. 2-Amino-Nicotinamide Derivatives and Their Use as VEGF-receptor Tyrosine Kinase Inhibitors. WO 01/55114.
11. 2, 100 mM NaCl, 1.5 mM EGTA, 1 mM DTT, 0.2 mM SOV, and 20 μg /mL BSA (40 μL to 100 mL buffer/60 μL to 150 mL buffer). HTRF buffer: 50 mM Tris-HCL, pH 7.5, 100 mM NaCl, 0.1% BSA, and 0.05% Tween 20.